NewAmsterdam Pharma (NAMS) Competitors

NewAmsterdam Pharma (NASDAQ:NAMS) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Is NAMS or BPMC more profitable?

NewAmsterdam Pharma has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. NewAmsterdam Pharma's return on equity of 0.00% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	N/A	N/A	N/A
Blueprint Medicines	-13.19%	-77.49%	-20.84%

Does the MarketBeat Community prefer NAMS or BPMC?

Blueprint Medicines received 524 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 90.91% of users gave NewAmsterdam Pharma an outperform vote while only 66.99% of users gave Blueprint Medicines an outperform vote.

Company	Underperform	Outperform
NewAmsterdam Pharma	Outperform Votes 30 90.91%	Underperform Votes 3 9.09%
Blueprint Medicines	Outperform Votes 554 66.99%	Underperform Votes 273 33.01%

Which has more risk and volatility, NAMS or BPMC?

NewAmsterdam Pharma has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.

Do analysts rate NAMS or BPMC?

NewAmsterdam Pharma currently has a consensus price target of $43.00, suggesting a potential upside of 109.76%. Blueprint Medicines has a consensus price target of $129.35, suggesting a potential upside of 1.10%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe NewAmsterdam Pharma is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Blueprint Medicines	0 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32

Which has preferable earnings and valuation, NAMS or BPMC?

Blueprint Medicines has higher revenue and earnings than NewAmsterdam Pharma. Blueprint Medicines is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$47.14M	48.82	-$176.94M	-$1.88	-10.90
Blueprint Medicines	$562.12M	14.70	-$67.09M	-$2.47	-51.80

Does the media favor NAMS or BPMC?

In the previous week, NewAmsterdam Pharma had 12 more articles in the media than Blueprint Medicines. MarketBeat recorded 31 mentions for NewAmsterdam Pharma and 19 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.56 beat NewAmsterdam Pharma's score of 0.53 indicating that Blueprint Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	10 Very Positive mention(s)	1 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Blueprint Medicines	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals believe in NAMS or BPMC?

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

NewAmsterdam Pharma beats Blueprint Medicines on 13 of the 19 factors compared between the two stocks.